Optiscan Imaging (OIL) AGM 2025 Presentation summary

Leadership and organisational readiness

• Board and executive team bring decades of experience in healthcare, medtech, finance, and global business leadership.

• Strengthened leadership with new finance and executive appointments to support global growth and commercialisation.

• Organisational structure and capability built to enable global scaling and strategic growth.

Technology and product development

• Three cornerstone devices—InForm™, InVueⓇ, and InSpecta™—progressed to clinical and commercial stages, targeting pathology, surgery, and veterinary markets.

• Telepathology Platform reached MVP, enabling real-time remote diagnostics and image review.

• AI-based imaging capabilities advanced for gastrointestinal and pathology applications, with clinical studies underway.

• New probe and scanner designs validated and delivered for clinical programs.

Clinical and regulatory milestones

• Ethical and regulatory approvals achieved for multiple studies, including breast cancer and GI studies in Australia and Germany.

• Clinical validation data generated to support regulatory submissions and future market entry.

• Comprehensive documentation, testing, and certification progressed for key devices in preparation for US-based clinical studies.